Everest Medicines

News

15 2020/09

Everest Medicines Announces Top-line Results from Phase 1 Clinical Trial of Taniborbactam in Combination with Cefepime in China
08 2020/09

Everest Medicines Announces First Patient Randomized in a Phase 3 Clinical Study of Nefecon for IgA Nephropathy Patients in China
28 2020/08

Everest Medicines Completes Enrollment of Phase 3 Clinical Trial of Xerava^™ (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections in China
07 2020/08

Everest Medicines Announces First Patient Dosed in a Phase 1b/2 Study of FGF401 in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors
22 2020/06

Everest Medicines Announces Positive Results of In Vitro Study of Xerava^™ (eravacycline) Against Human Mycoplasmas
04 2020/06

Everest Medicines Completes US$310 Million Series C Financing
24 2020/04

Everest Medicines Announces That Licensing Partner Immunomedics has Received FDA Accelerated Approval for Trodelvy (sacituzumab govitecan-hziy) in Previously-treated Metastatic Triple-Negative Breast
22 2020/04

Everest Medicines Announces Approval of Clinical Trial Application by China National Medical Products Administration to Initiate China Registration Study of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer
17 2020/04

Everest Medicines Announces Approval of Xerava™ from the Health Science Authority in Singapore for the Treatment of Complicated Intra-Abdominal Infections
09 2020/04

Everest Medicines Announces Positive Results from In Vitro Study of Taniborbactam (VNRX-5133) in Combination with Cefepime
17 2020/03

Everest Medicines Forms Strategic Partnership with Jiashan National Economic and Technological Development Zone and Jiashan SDIC
20 2020/02

Everest Medicines Appoints Kerry Blanchard, M.D., Ph.D., as Director and Chief Executive Officer

Copyright Everest Medicines 2020 云顶药业（苏州）有限公司苏ICP备20038571号 | Terms of Use | Privacy Policy | Disclaimers

沪公网安备 31010602006477号